Literature DB >> 30796567

Clinical significance of evaluating coronary atherosclerosis in adult patients with hypertrophic cardiomyopathy who have chest pain.

Yoon Joo Shin1, Jae Hwan Lee2, Jin Young Yoo3, Jeong A Kim4, Yongho Jeon5, Yeonyee E Yoon6, Eun Ju Chun7.   

Abstract

OBJECTIVE: Chest pain is a common symptom in patients with hypertrophic cardiomyopathy (HCM), causing difficulty determining whether there is coexistent coronary artery disease (CAD). We investigated whether coronary computed tomography angiography (CCTA) can assess the prevalence and clinical significance of CAD in adult patients with HCM showing chest pain through longitudinal follow-up.
METHODS: In 238 adult patients with HCM, who underwent CCTA for chest pain, we analyzed the degree of stenosis and adverse plaque characteristics (APCs) as CCTA variables. Three prediction models for adverse cardiovascular events (ACEs: all-cause mortality, myocardial infarction, unstable angina, heart failure, implantable cardioverter-defibrillator implantation, and stroke) were assessed using the combination of clinical risk factors, echocardiographic parameters, and CCTA variables.
RESULTS: The prevalence of obstructive CAD (≥ 50% in luminal stenosis) and APC was 14.7% and 18.9%, respectively. During the follow-up period (median, 37 months; range, 2-108 months), there were 31 occurrences of ACEs (13.0%). Using multivariate Cox regression analysis, age, atrial fibrillation, low ejection fraction, obstructive CAD, and APCs were associated with ACEs (all p < 0.05). Among the prediction models for ACEs, the area under the curve (AUC) was higher (AUC = 0.92) when CCTA variables were added to the clinical (AUC = 0.84) and echocardiographic factors (AUC = 0.88) (p < 0.001).
CONCLUSIONS: Using CCTA, about 20% of symptomatic HCM patients were associated with clinically significant atherosclerosis. Adding these CCTA variables to the clinical and echocardiographic variables may increase the predictions of ACEs; therefore, evaluating coronary atherosclerosis using CCTA may be helpful for symptomatic HCM patients. KEY POINTS: • Chest pain in adult patients with hypertrophic cardiomyopathy (HCM) remains challenging to distinguish from coronary artery disease. • Coronary computed tomography angiography (CCTA) can assess the severity and characteristics of coronary atherosclerosis in symptomatic HCM patients. • Adding CCTA variables to clinical and echocardiographic factors may increase the predictions of adverse cardiac events in HCM patients, and thus evaluating coronary atherosclerosis using CCTA may be helpful for HCM patients with chest pain.

Entities:  

Keywords:  Cardiomyopathy, hypertrophic; Chest pain; Computed tomography angiography; Coronary artery disease

Mesh:

Year:  2019        PMID: 30796567     DOI: 10.1007/s00330-018-5951-8

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  39 in total

Review 1.  American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.

Authors:  G S Mintz; S E Nissen; W D Anderson; S R Bailey; R Erbel; P J Fitzgerald; F J Pinto; K Rosenfield; R J Siegel; E M Tuzcu; P G Yock
Journal:  J Am Coll Cardiol       Date:  2001-04       Impact factor: 24.094

Review 2.  Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions.

Authors:  R Virmani; F D Kolodgie; A P Burke; A Farb; S M Schwartz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-05       Impact factor: 8.311

Review 3.  Clinical practice. Hypertrophic obstructive cardiomyopathy.

Authors:  Rick A Nishimura; David R Holmes
Journal:  N Engl J Med       Date:  2004-03-25       Impact factor: 91.245

4.  Hypertrophic cardiomyopathy with persistent ST segment elevation simulating acute myocardial infarction.

Authors:  F Luzza; S Carerj; G Oreto
Journal:  Heart       Date:  2004-04       Impact factor: 5.994

Review 5.  Hypertrophic cardiomyopathy: a systematic review.

Authors:  Barry J Maron
Journal:  JAMA       Date:  2002-03-13       Impact factor: 56.272

Review 6.  Myocardial bridging.

Authors:  Jorge R Alegria; Joerg Herrmann; David R Holmes; Amir Lerman; Charanjit S Rihal
Journal:  Eur Heart J       Date:  2005-03-11       Impact factor: 29.983

7.  Hypertrophic cardiomyopathy and associated coronary artery disease.

Authors:  D V Cokkinos; Z Krajcer; R D Leachman
Journal:  Tex Heart Inst J       Date:  1985-06

8.  Myocardial bridging in adult patients with hypertrophic cardiomyopathy.

Authors:  Paul Sorajja; Steve R Ommen; Rick A Nishimura; Bernard J Gersh; A Jamil Tajik; David R Holmes
Journal:  J Am Coll Cardiol       Date:  2003-09-03       Impact factor: 24.094

9.  Clinical course of hypertrophic cardiomyopathy with survival to advanced age.

Authors:  Barry J Maron; Susan A Casey; Robert G Hauser; Dorothee M Aeppli
Journal:  J Am Coll Cardiol       Date:  2003-09-03       Impact factor: 24.094

10.  Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease.

Authors:  Paul Sorajja; Steve R Ommen; Rick A Nishimura; Bernard J Gersh; Peter B Berger; A Jamil Tajik
Journal:  Circulation       Date:  2003-10-27       Impact factor: 29.690

View more
  2 in total

1.  Combined evaluation of coronary artery disease and high-sensitivity cardiac troponin T for prediction of adverse events in patients with hypertrophic cardiomyopathy.

Authors:  Hang Liao; Huay Cheem Tan; Ziqiong Wang; Xiaoping Chen; Yong He; Sen He
Journal:  BMC Cardiovasc Disord       Date:  2021-07-03       Impact factor: 2.298

2.  G protein-coupled receptor 39 activation alleviates oxidized low-density lipoprotein-induced macrophage inflammatory response, lipid accumulation and apoptosis by inducing A20 expression.

Authors:  Lu Chen; Zhengdong Fang; Xiaotian Wang; Xiaojie Sun; Xinbao Ge; Can Cheng; Hejie Hu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.